【复星医药(02196.HK)：复迈宁®用于治疗儿童低级别脑胶质瘤于中国境内启动Ⅲ期临床试验】智通财经APP讯，复星医药(02196.HK)发布公告，该公司控股子公司上海复星医药产业发展有限公司就复迈宁®(通用名：芦沃美替尼片，以下简称“该药品”)用于治疗儿童低级别脑胶质瘤于中国境内(不包括港澳台地区，下同)启动Ⅲ期临床试验。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.